Page last updated: 2024-08-21

aminoimidazole carboxamide and Dysmyelopoietic Syndromes

aminoimidazole carboxamide has been researched along with Dysmyelopoietic Syndromes in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Li, X; Liang, L; Liu, J; Nie, L; Peng, YL; Wang, XL; Zhang, J	1

Other Studies

1 other study(ies) available for aminoimidazole carboxamide and Dysmyelopoietic Syndromes

Article	Year
AICAR suppresses cell proliferation and synergizes with decitabine in myelodysplastic syndrome via DNA damage induction. Biotechnology letters, 2021, Volume: 43, Issue:6 Topics: Adenylate Kinase; Aminoimidazole Carboxamide; AMP-Activated Protein Kinase Kinases; Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Decitabine; DNA Damage; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Mice; Myelodysplastic Syndromes; Ribonucleotides; Xenograft Model Antitumor Assays	2021

Article

Year

AICAR suppresses cell proliferation and synergizes with decitabine in myelodysplastic syndrome via DNA damage induction.

Biotechnology letters, 2021, Volume: 43, Issue:6

Topics: Adenylate Kinase; Aminoimidazole Carboxamide; AMP-Activated Protein Kinase Kinases; Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Decitabine; DNA Damage; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Mice; Myelodysplastic Syndromes; Ribonucleotides; Xenograft Model Antitumor Assays

2021